A phase III CROWN study's patient-reported outcomes showed that the time to treatment deterioration (TTD) in chest pain, shortness of breath, and cough was comparable between those who received lorlatinib and patients who took crizotinib.
The study was presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.
Lorlatinib is a third generation ALK inhibitor that has significantly improved progression-free survival when compared to crizotinib ...
A phase III CROWN study's patient-reported outcomes showed that the time to treatment deterioration (TTD) in chest pain, shortness of breath, and cough was comparable between those who received lorlatinib and patients who took crizotinib.
The study was presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.
Lorlatinib is a third generation ALK inhibitor that has significantly improved progression-free survival when compared to crizotinib ...